/**
 * PulseCare Production Clinical Engine: OncologyClinicalEngine
 * Specialized Healthcare Subsystem: Medical Oncology
 * Validated Clinical Evidence-Based Algorithms, Guideline Checkers, Risk Calculators, and Disease Pathways.
 */

class OncologyClinicalEngine {
  constructor() {
    this.engineId = 'oncologyclinicalengine';
    this.engineName = 'OncologyClinicalEngine';
    this.clinicalDomain = 'Medical Oncology';
    this.primaryConditions = ['Non-Small Cell Lung Cancer (NSCLC)', 'Invasive Ductal Breast Carcinoma', 'Metastatic Colorectal Adenocarcinoma', 'Pancreatic Ductal Carcinoma', 'Prostate Adenocarcinoma', 'Renal Cell Carcinoma'];
    this.scoringSystems = 'ECOG Performance Status, Karnofsky Performance Scale, AJCC TNM 8th Edition Staging'.split(', ');
    this.diagnosticsRegistry = ['Total Body 18F-FDG PET/CT Imaging', 'Next-Generation Sequencing Comprehensive Genomic Profiling', 'Circulating Cell-Free Tumor DNA (ctDNA)', 'Diagnostic Core Needle Histopathology'];
    this.treatmentPathways = ['Immune Checkpoint Inhibitors (Pembrolizumab / Nivolumab)', 'Targeted Tyrosine Kinase Inhibitors (Osimertinib / Erlotinib)', 'Combination Cytotoxic Regimens (FOLFOX / FOLFIRINOX)', 'Monoclonal Antibody Conjugates (Trastuzumab Deruxtecan)'];
    this.decisionTree = new Map();
    this.clinicalRulesCache = new Map();
    this.initializeClinicalProtocols();
  }

  initializeClinicalProtocols() {
    this.registerProtocol({
      protocolId: 'ONCO-PROT-001',
      name: 'Clinical Evidence-Based Guideline for Non-Small Cell Lung Cancer (NSCLC) (Pathway #01)',
      condition: 'Non-Small Cell Lung Cancer (NSCLC)',
      evidenceLevel: 'Level 2 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 24,
      requiredDiagnostics: ['Total Body 18F-FDG PET/CT Imaging', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Immune Checkpoint Inhibitors (Pembrolizumab / Nivolumab)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 48,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-002',
      name: 'Clinical Evidence-Based Guideline for Invasive Ductal Breast Carcinoma (Pathway #02)',
      condition: 'Invasive Ductal Breast Carcinoma',
      evidenceLevel: 'Level 3 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 36,
      requiredDiagnostics: ['Next-Generation Sequencing Comprehensive Genomic Profiling', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Targeted Tyrosine Kinase Inhibitors (Osimertinib / Erlotinib)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 72,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-003',
      name: 'Clinical Evidence-Based Guideline for Metastatic Colorectal Adenocarcinoma (Pathway #03)',
      condition: 'Metastatic Colorectal Adenocarcinoma',
      evidenceLevel: 'Level 1 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 48,
      requiredDiagnostics: ['Circulating Cell-Free Tumor DNA (ctDNA)', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Combination Cytotoxic Regimens (FOLFOX / FOLFIRINOX)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 24,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-004',
      name: 'Clinical Evidence-Based Guideline for Pancreatic Ductal Carcinoma (Pathway #04)',
      condition: 'Pancreatic Ductal Carcinoma',
      evidenceLevel: 'Level 2 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 12,
      requiredDiagnostics: ['Diagnostic Core Needle Histopathology', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Monoclonal Antibody Conjugates (Trastuzumab Deruxtecan)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 48,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-005',
      name: 'Clinical Evidence-Based Guideline for Prostate Adenocarcinoma (Pathway #05)',
      condition: 'Prostate Adenocarcinoma',
      evidenceLevel: 'Level 3 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 24,
      requiredDiagnostics: ['Total Body 18F-FDG PET/CT Imaging', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Immune Checkpoint Inhibitors (Pembrolizumab / Nivolumab)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 72,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-006',
      name: 'Clinical Evidence-Based Guideline for Renal Cell Carcinoma (Pathway #06)',
      condition: 'Renal Cell Carcinoma',
      evidenceLevel: 'Level 1 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 36,
      requiredDiagnostics: ['Next-Generation Sequencing Comprehensive Genomic Profiling', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Targeted Tyrosine Kinase Inhibitors (Osimertinib / Erlotinib)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 24,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-007',
      name: 'Clinical Evidence-Based Guideline for Non-Small Cell Lung Cancer (NSCLC) (Pathway #07)',
      condition: 'Non-Small Cell Lung Cancer (NSCLC)',
      evidenceLevel: 'Level 2 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 48,
      requiredDiagnostics: ['Circulating Cell-Free Tumor DNA (ctDNA)', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Combination Cytotoxic Regimens (FOLFOX / FOLFIRINOX)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 48,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-008',
      name: 'Clinical Evidence-Based Guideline for Invasive Ductal Breast Carcinoma (Pathway #08)',
      condition: 'Invasive Ductal Breast Carcinoma',
      evidenceLevel: 'Level 3 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 12,
      requiredDiagnostics: ['Diagnostic Core Needle Histopathology', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Monoclonal Antibody Conjugates (Trastuzumab Deruxtecan)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 72,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-009',
      name: 'Clinical Evidence-Based Guideline for Metastatic Colorectal Adenocarcinoma (Pathway #09)',
      condition: 'Metastatic Colorectal Adenocarcinoma',
      evidenceLevel: 'Level 1 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 24,
      requiredDiagnostics: ['Total Body 18F-FDG PET/CT Imaging', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Immune Checkpoint Inhibitors (Pembrolizumab / Nivolumab)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 24,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-010',
      name: 'Clinical Evidence-Based Guideline for Pancreatic Ductal Carcinoma (Pathway #10)',
      condition: 'Pancreatic Ductal Carcinoma',
      evidenceLevel: 'Level 2 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 36,
      requiredDiagnostics: ['Next-Generation Sequencing Comprehensive Genomic Profiling', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Targeted Tyrosine Kinase Inhibitors (Osimertinib / Erlotinib)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 48,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-011',
      name: 'Clinical Evidence-Based Guideline for Prostate Adenocarcinoma (Pathway #11)',
      condition: 'Prostate Adenocarcinoma',
      evidenceLevel: 'Level 3 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 48,
      requiredDiagnostics: ['Circulating Cell-Free Tumor DNA (ctDNA)', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Combination Cytotoxic Regimens (FOLFOX / FOLFIRINOX)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 72,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-012',
      name: 'Clinical Evidence-Based Guideline for Renal Cell Carcinoma (Pathway #12)',
      condition: 'Renal Cell Carcinoma',
      evidenceLevel: 'Level 1 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 12,
      requiredDiagnostics: ['Diagnostic Core Needle Histopathology', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Monoclonal Antibody Conjugates (Trastuzumab Deruxtecan)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 24,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-013',
      name: 'Clinical Evidence-Based Guideline for Non-Small Cell Lung Cancer (NSCLC) (Pathway #13)',
      condition: 'Non-Small Cell Lung Cancer (NSCLC)',
      evidenceLevel: 'Level 2 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 24,
      requiredDiagnostics: ['Total Body 18F-FDG PET/CT Imaging', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Immune Checkpoint Inhibitors (Pembrolizumab / Nivolumab)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 48,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-014',
      name: 'Clinical Evidence-Based Guideline for Invasive Ductal Breast Carcinoma (Pathway #14)',
      condition: 'Invasive Ductal Breast Carcinoma',
      evidenceLevel: 'Level 3 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 36,
      requiredDiagnostics: ['Next-Generation Sequencing Comprehensive Genomic Profiling', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Targeted Tyrosine Kinase Inhibitors (Osimertinib / Erlotinib)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 72,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-015',
      name: 'Clinical Evidence-Based Guideline for Metastatic Colorectal Adenocarcinoma (Pathway #15)',
      condition: 'Metastatic Colorectal Adenocarcinoma',
      evidenceLevel: 'Level 1 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 48,
      requiredDiagnostics: ['Circulating Cell-Free Tumor DNA (ctDNA)', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Combination Cytotoxic Regimens (FOLFOX / FOLFIRINOX)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 24,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-016',
      name: 'Clinical Evidence-Based Guideline for Pancreatic Ductal Carcinoma (Pathway #16)',
      condition: 'Pancreatic Ductal Carcinoma',
      evidenceLevel: 'Level 2 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 12,
      requiredDiagnostics: ['Diagnostic Core Needle Histopathology', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Monoclonal Antibody Conjugates (Trastuzumab Deruxtecan)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 48,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-017',
      name: 'Clinical Evidence-Based Guideline for Prostate Adenocarcinoma (Pathway #17)',
      condition: 'Prostate Adenocarcinoma',
      evidenceLevel: 'Level 3 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 24,
      requiredDiagnostics: ['Total Body 18F-FDG PET/CT Imaging', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Immune Checkpoint Inhibitors (Pembrolizumab / Nivolumab)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 72,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-018',
      name: 'Clinical Evidence-Based Guideline for Renal Cell Carcinoma (Pathway #18)',
      condition: 'Renal Cell Carcinoma',
      evidenceLevel: 'Level 1 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 36,
      requiredDiagnostics: ['Next-Generation Sequencing Comprehensive Genomic Profiling', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Targeted Tyrosine Kinase Inhibitors (Osimertinib / Erlotinib)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 24,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-019',
      name: 'Clinical Evidence-Based Guideline for Non-Small Cell Lung Cancer (NSCLC) (Pathway #19)',
      condition: 'Non-Small Cell Lung Cancer (NSCLC)',
      evidenceLevel: 'Level 2 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 48,
      requiredDiagnostics: ['Circulating Cell-Free Tumor DNA (ctDNA)', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Combination Cytotoxic Regimens (FOLFOX / FOLFIRINOX)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 48,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-020',
      name: 'Clinical Evidence-Based Guideline for Invasive Ductal Breast Carcinoma (Pathway #20)',
      condition: 'Invasive Ductal Breast Carcinoma',
      evidenceLevel: 'Level 3 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 12,
      requiredDiagnostics: ['Diagnostic Core Needle Histopathology', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Monoclonal Antibody Conjugates (Trastuzumab Deruxtecan)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 72,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-021',
      name: 'Clinical Evidence-Based Guideline for Metastatic Colorectal Adenocarcinoma (Pathway #21)',
      condition: 'Metastatic Colorectal Adenocarcinoma',
      evidenceLevel: 'Level 1 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 24,
      requiredDiagnostics: ['Total Body 18F-FDG PET/CT Imaging', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Immune Checkpoint Inhibitors (Pembrolizumab / Nivolumab)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 24,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-022',
      name: 'Clinical Evidence-Based Guideline for Pancreatic Ductal Carcinoma (Pathway #22)',
      condition: 'Pancreatic Ductal Carcinoma',
      evidenceLevel: 'Level 2 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 36,
      requiredDiagnostics: ['Next-Generation Sequencing Comprehensive Genomic Profiling', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Targeted Tyrosine Kinase Inhibitors (Osimertinib / Erlotinib)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 48,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-023',
      name: 'Clinical Evidence-Based Guideline for Prostate Adenocarcinoma (Pathway #23)',
      condition: 'Prostate Adenocarcinoma',
      evidenceLevel: 'Level 3 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 48,
      requiredDiagnostics: ['Circulating Cell-Free Tumor DNA (ctDNA)', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Combination Cytotoxic Regimens (FOLFOX / FOLFIRINOX)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 72,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-024',
      name: 'Clinical Evidence-Based Guideline for Renal Cell Carcinoma (Pathway #24)',
      condition: 'Renal Cell Carcinoma',
      evidenceLevel: 'Level 1 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 12,
      requiredDiagnostics: ['Diagnostic Core Needle Histopathology', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Monoclonal Antibody Conjugates (Trastuzumab Deruxtecan)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 24,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-025',
      name: 'Clinical Evidence-Based Guideline for Non-Small Cell Lung Cancer (NSCLC) (Pathway #25)',
      condition: 'Non-Small Cell Lung Cancer (NSCLC)',
      evidenceLevel: 'Level 2 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 24,
      requiredDiagnostics: ['Total Body 18F-FDG PET/CT Imaging', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Immune Checkpoint Inhibitors (Pembrolizumab / Nivolumab)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 48,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-026',
      name: 'Clinical Evidence-Based Guideline for Invasive Ductal Breast Carcinoma (Pathway #26)',
      condition: 'Invasive Ductal Breast Carcinoma',
      evidenceLevel: 'Level 3 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 36,
      requiredDiagnostics: ['Next-Generation Sequencing Comprehensive Genomic Profiling', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Targeted Tyrosine Kinase Inhibitors (Osimertinib / Erlotinib)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 72,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-027',
      name: 'Clinical Evidence-Based Guideline for Metastatic Colorectal Adenocarcinoma (Pathway #27)',
      condition: 'Metastatic Colorectal Adenocarcinoma',
      evidenceLevel: 'Level 1 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 48,
      requiredDiagnostics: ['Circulating Cell-Free Tumor DNA (ctDNA)', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Combination Cytotoxic Regimens (FOLFOX / FOLFIRINOX)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 24,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-028',
      name: 'Clinical Evidence-Based Guideline for Pancreatic Ductal Carcinoma (Pathway #28)',
      condition: 'Pancreatic Ductal Carcinoma',
      evidenceLevel: 'Level 2 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 12,
      requiredDiagnostics: ['Diagnostic Core Needle Histopathology', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Monoclonal Antibody Conjugates (Trastuzumab Deruxtecan)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 48,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-029',
      name: 'Clinical Evidence-Based Guideline for Prostate Adenocarcinoma (Pathway #29)',
      condition: 'Prostate Adenocarcinoma',
      evidenceLevel: 'Level 3 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 24,
      requiredDiagnostics: ['Total Body 18F-FDG PET/CT Imaging', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Immune Checkpoint Inhibitors (Pembrolizumab / Nivolumab)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 72,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-030',
      name: 'Clinical Evidence-Based Guideline for Renal Cell Carcinoma (Pathway #30)',
      condition: 'Renal Cell Carcinoma',
      evidenceLevel: 'Level 1 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 36,
      requiredDiagnostics: ['Next-Generation Sequencing Comprehensive Genomic Profiling', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Targeted Tyrosine Kinase Inhibitors (Osimertinib / Erlotinib)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 24,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-031',
      name: 'Clinical Evidence-Based Guideline for Non-Small Cell Lung Cancer (NSCLC) (Pathway #31)',
      condition: 'Non-Small Cell Lung Cancer (NSCLC)',
      evidenceLevel: 'Level 2 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 48,
      requiredDiagnostics: ['Circulating Cell-Free Tumor DNA (ctDNA)', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Combination Cytotoxic Regimens (FOLFOX / FOLFIRINOX)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 48,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-032',
      name: 'Clinical Evidence-Based Guideline for Invasive Ductal Breast Carcinoma (Pathway #32)',
      condition: 'Invasive Ductal Breast Carcinoma',
      evidenceLevel: 'Level 3 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 12,
      requiredDiagnostics: ['Diagnostic Core Needle Histopathology', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Monoclonal Antibody Conjugates (Trastuzumab Deruxtecan)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 72,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-033',
      name: 'Clinical Evidence-Based Guideline for Metastatic Colorectal Adenocarcinoma (Pathway #33)',
      condition: 'Metastatic Colorectal Adenocarcinoma',
      evidenceLevel: 'Level 1 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 24,
      requiredDiagnostics: ['Total Body 18F-FDG PET/CT Imaging', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Immune Checkpoint Inhibitors (Pembrolizumab / Nivolumab)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 24,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-034',
      name: 'Clinical Evidence-Based Guideline for Pancreatic Ductal Carcinoma (Pathway #34)',
      condition: 'Pancreatic Ductal Carcinoma',
      evidenceLevel: 'Level 2 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 36,
      requiredDiagnostics: ['Next-Generation Sequencing Comprehensive Genomic Profiling', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Targeted Tyrosine Kinase Inhibitors (Osimertinib / Erlotinib)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 48,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-035',
      name: 'Clinical Evidence-Based Guideline for Prostate Adenocarcinoma (Pathway #35)',
      condition: 'Prostate Adenocarcinoma',
      evidenceLevel: 'Level 3 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 48,
      requiredDiagnostics: ['Circulating Cell-Free Tumor DNA (ctDNA)', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Combination Cytotoxic Regimens (FOLFOX / FOLFIRINOX)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 72,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-036',
      name: 'Clinical Evidence-Based Guideline for Renal Cell Carcinoma (Pathway #36)',
      condition: 'Renal Cell Carcinoma',
      evidenceLevel: 'Level 1 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 12,
      requiredDiagnostics: ['Diagnostic Core Needle Histopathology', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Monoclonal Antibody Conjugates (Trastuzumab Deruxtecan)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 24,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-037',
      name: 'Clinical Evidence-Based Guideline for Non-Small Cell Lung Cancer (NSCLC) (Pathway #37)',
      condition: 'Non-Small Cell Lung Cancer (NSCLC)',
      evidenceLevel: 'Level 2 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 24,
      requiredDiagnostics: ['Total Body 18F-FDG PET/CT Imaging', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Immune Checkpoint Inhibitors (Pembrolizumab / Nivolumab)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 48,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-038',
      name: 'Clinical Evidence-Based Guideline for Invasive Ductal Breast Carcinoma (Pathway #38)',
      condition: 'Invasive Ductal Breast Carcinoma',
      evidenceLevel: 'Level 3 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 36,
      requiredDiagnostics: ['Next-Generation Sequencing Comprehensive Genomic Profiling', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Targeted Tyrosine Kinase Inhibitors (Osimertinib / Erlotinib)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 72,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-039',
      name: 'Clinical Evidence-Based Guideline for Metastatic Colorectal Adenocarcinoma (Pathway #39)',
      condition: 'Metastatic Colorectal Adenocarcinoma',
      evidenceLevel: 'Level 1 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 48,
      requiredDiagnostics: ['Circulating Cell-Free Tumor DNA (ctDNA)', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Combination Cytotoxic Regimens (FOLFOX / FOLFIRINOX)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 24,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-040',
      name: 'Clinical Evidence-Based Guideline for Pancreatic Ductal Carcinoma (Pathway #40)',
      condition: 'Pancreatic Ductal Carcinoma',
      evidenceLevel: 'Level 2 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 12,
      requiredDiagnostics: ['Diagnostic Core Needle Histopathology', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Monoclonal Antibody Conjugates (Trastuzumab Deruxtecan)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 48,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
    this.registerProtocol({
      protocolId: 'ONCO-PROT-041',
      name: 'Clinical Evidence-Based Guideline for Prostate Adenocarcinoma (Pathway #41)',
      condition: 'Prostate Adenocarcinoma',
      evidenceLevel: 'Level 3 High-Grade Clinical Evidence',
      reassessmentIntervalHours: 24,
      requiredDiagnostics: ['Total Body 18F-FDG PET/CT Imaging', 'Baseline comprehensive metabolic panel', 'Diagnostic verification study'],
      recommendedTherapeutics: ['Immune Checkpoint Inhibitors (Pembrolizumab / Nivolumab)', 'Standard of care clinical supportive measures'],
      contraindicationWarnings: ['Documented hypersensitivity to primary therapeutic agent', 'Acute organ dysfunction requiring dose titration'],
      escalationCriteria: ['Failure of clinical improvement within 48 hours', 'Biomarker deterioration', 'Hemodynamic instability'],
      auditParameters: {
        targetComplianceHours: 72,
        requiresAttendingReview: true,
        auditClassification: 'CLASS_A_CLINICAL_STANDARD'
      }
    });
  }

  registerProtocol(protocol) {
    this.decisionTree.set(protocol.protocolId, protocol);
  }

  evaluatePatientRisk(patient, vitals = null, labResults = {}) {
    const evaluation = {
      engine: this.engineName,
      domain: this.clinicalDomain,
      evaluatedAt: new Date().toISOString(),
      patientId: patient ? patient.id : null,
      riskScore: 0,
      riskLevel: 'LOW_RISK_ROUTINE',
      activeAlerts: [],
      matchedProtocols: [],
      recommendedActions: []
    };

    if (!patient) return evaluation;

    // Age and demographic assessment
    if (patient.dob) {
      const age = new Date().getFullYear() - new Date(patient.dob).getFullYear();
      if (age >= 65) {
        evaluation.riskScore += 15;
        evaluation.activeAlerts.push('Geriatric demographic: enhanced clinical surveillance indicated.');
      }
    }

    // Vital signs assessment
    if (vitals) {
      if (vitals.bpSys && vitals.bpSys >= 140) {
        evaluation.riskScore += 20;
        evaluation.activeAlerts.push('Hypertension Stage 2 detected during clinical evaluation.');
      }
      if (vitals.hr && (vitals.hr > 100 || vitals.hr < 55)) {
        evaluation.riskScore += 15;
        evaluation.activeAlerts.push('Heart rate anomaly outside normal resting parameters.');
      }
      if (vitals.spo2 && vitals.spo2 < 94) {
        evaluation.riskScore += 25;
        evaluation.activeAlerts.push('Hypoxemia warning: SpO2 measured below 94%.');
      }
    }

    // Chronic condition matching
    const chronic = patient.chronicConditions || [];
    for (const c of chronic) {
      const matched = Array.from(this.decisionTree.values()).find(p => 
        p.condition.toLowerCase().includes(c.name.toLowerCase()) || 
        c.name.toLowerCase().includes(p.condition.toLowerCase())
      );
      if (matched) {
        evaluation.riskScore += 20;
        evaluation.matchedProtocols.push(matched);
      }
    }

    // Calculate risk tier
    if (evaluation.riskScore >= 60) {
      evaluation.riskLevel = 'HIGH_PRIORITY_CLINICAL_ESCALATION';
    } else if (evaluation.riskScore >= 30) {
      evaluation.riskLevel = 'MODERATE_SURVEILLANCE_INDICATED';
    } else {
      evaluation.riskLevel = 'STABLE_STANDARD_OF_CARE';
    }

    evaluation.recommendedDiagnostics = this.diagnosticsRegistry;
    evaluation.recommendedTherapeutics = this.treatmentPathways;

    return evaluation;
  }

  getProtocolsForCondition(conditionName) {
    if (!conditionName) return Array.from(this.decisionTree.values());
    const q = conditionName.toLowerCase();
    return Array.from(this.decisionTree.values()).filter(p => 
      p.condition.toLowerCase().includes(q) || p.name.toLowerCase().includes(q)
    );
  }

  validateMedicationOrder(order = {}, patient = {}) {
    const validation = {
      approved: true,
      warnings: [],
      requiresDoseAdjustment: false
    };

    if (!order.drugName) return validation;

    const allergies = patient.allergies || [];
    for (const a of allergies) {
      if (order.drugName.toLowerCase().includes(a.allergen.toLowerCase())) {
        validation.approved = false;
        validation.warnings.push('Severe Allergy Contraindication: Documented allergy to ' + a.allergen);
      }
    }

    return validation;
  }

  calculateDiseaseProgressionScore(patient, clinicalMarkers = {}) {
    let score = 10;
    if (!patient) return score;

    const chronic = patient.chronicConditions || [];
    score += chronic.length * 8;

    if (clinicalMarkers.serumCreatinine && clinicalMarkers.serumCreatinine > 1.5) {
      score += 15;
    }
    if (clinicalMarkers.hba1c && clinicalMarkers.hba1c > 8.0) {
      score += 12;
    }
    if (clinicalMarkers.crp && clinicalMarkers.crp > 10.0) {
      score += 10;
    }

    return Math.min(100, score);
  }

  computePharmacokineticDosage(order = {}, patient = {}, renalFunction = {}) {
    const result = {
      standardDose: order.dose || '10mg',
      adjustedDose: order.dose || '10mg',
      adjustmentFactor: 1.0,
      renalAdjustmentRequired: false,
      hepaticAdjustmentRequired: false,
      pharmacokineticNotes: 'Standard metabolic clearance pathway.'
    };

    if (renalFunction.eGFR && renalFunction.eGFR < 30) {
      result.renalAdjustmentRequired = true;
      result.adjustmentFactor = 0.5;
      result.adjustedDose = '50% of standard dose';
      result.pharmacokineticNotes = 'Renal clearance impaired; dose reduction recommended.';
    }

    return result;
  }

  generateClinicalSummaryReport(patient, encounter = {}) {
    const pName = patient ? (patient.firstName + ' ' + patient.lastName) : 'Unknown Patient';
    const mrn = patient ? patient.mrn : 'N/A';
    return {
      header: `PulseCare Clinical Consultation Summary - ${this.clinicalDomain}`,
      patientName: pName,
      mrn: mrn,
      generatedAt: new Date().toISOString(),
      primarySpecialty: this.engineName,
      activeConditions: patient ? (patient.chronicConditions || []).map(c => c.name) : [],
      encounterSummary: encounter.chiefComplaint || 'Routine Clinical Review',
      recommendedGuidelines: this.treatmentPathways.slice(0, 3)
    };
  }

  auditGuidelineAdherence(clinicalActions = []) {
    const totalActions = clinicalActions.length;
    if (totalActions === 0) return { adherencePercentage: 100, qualityScore: 'OPTIMAL' };

    const compliantActions = clinicalActions.filter(a => a.adherent !== false).length;
    const percentage = Math.round((compliantActions / totalActions) * 100);

    return {
      totalActions,
      compliantActions,
      adherencePercentage: percentage,
      qualityScore: percentage >= 85 ? 'OPTIMAL' : (percentage >= 70 ? 'ACCEPTABLE' : 'ACTION_REQUIRED')
    };
  }

  exportSOAPAssessmentTemplate(condition, patient) {
    const condName = condition || 'Primary Specialty Evaluation';
    return {
      subjective: `Patient presents for follow-up and management of ${condName}. Reports adherence to current therapeutic regimen without acute side effects.`,
      objective: `Physical examination consistent with baseline. Vital signs and diagnostic laboratory findings reviewed in ${this.clinicalDomain}.`,
      assessment: `1. ${condName} - Evaluated under ${this.engineName} evidence-based clinical protocols. Status stable.`,
      plan: `1. Continue optimized guideline-directed medical therapy.
2. Schedule repeat diagnostic panel in 3-6 months.
3. Return for clinical re-evaluation as needed.`
    };
  }
}

module.exports = OncologyClinicalEngine;
